SK Bioscience Co., Ltd.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 30, 2027The maintenance fee for Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method (US 11,883,483) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof (US 11,951,162) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,041,635 | Factor VIII polypeptide In force · USPTO record | In force | USPTO record | |
| US 9,441,030 | Process for producing and purifying factor VIII and its derivatives In force · USPTO record | In force | USPTO record | |
| US 9,926,361 | Process for producing and purifying factor VIII and its derivatives In force · USPTO record | In force | USPTO record | |
| US 9,447,383 | Mdck-Derived Cell Lines Adapted to Serum-Free Culture and Suspension Culture and Method for Preparing Vaccine Virus Using the Cells In force · Medium confidence | In force | Medium confidence | |
| US 9,636,392 | Production Method for Capsular Polysaccharide Having Pneumococcal Serotype In force · High confidence | In force | High confidence | |
| US 9,981,029 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition In force · High confidence | In force | High confidence | |
| US 11,224,652 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition In force · High confidence | In force | High confidence | |
| US 11,241,489 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition In force · High confidence | In force | High confidence | |
| US 11,883,483 | Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method In force · USPTO record | In force | USPTO record | |
| US 12,605,435 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 3 patents in force now held by others · 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 1 abandoned · 4 no status recorded
Showing 1 to 10 of 18, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/074,708 | Mar 10, 2025 | No status recorded | |
| 18/932,238 | Method And Apparatus For Designing Experiment | Oct 30, 2024 | Pending |
| 18/800,657 | Aug 12, 2024 | No status recorded | |
| 18/860,888 | Chimeric Zika Virus Anticancer Vaccine Obtained Through Breast Cancer Cell Passage | Apr 27, 2023 | Pending |
| 18/858,857 | Composition for Reducing Size or Volume of Target Tissue or Kit Including Same | Apr 24, 2023 | Pending |
| 18/730,572 | Mrna for Protein Expression and Template Therefor | Jan 20, 2023 | Pending |
| 18/696,130 | Recombinant Live Attenuated RSV Vaccine Strain and Production Method Therefor | Sep 29, 2022 | Pending |
| 18/294,013 | Method for Stably Maintaining Poly(A) Tail | Aug 17, 2022 | Pending |
| 18/291,888 | Mrna for Protein Expression and Template Therefor | Jul 14, 2022 | Pending |
| 18/576,816 | Method for Producing Reassortant Reoviridae Virus, and Vector Library for Same | Jun 24, 2022 | Pending |
10 of 18 applications shown.
Pro members see all 18 published applications.